Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

Autor:	Claudette Falato, Constanze Jonak, Rudolf Stadler, René Stranzenbach, Martine Bagot, Robert Knobler, Delphine Sartori, Pietro Quaglino, Julia Scarisbrick, Emmanuella Guenova, Jammbe Z. Musoro, E. Papadavid, Pablo Luis Ortiz Romero, Sandrine Marreaud
Rok vydání:	2021
Předmět:	Mycosis fungoides/Sezary syndrome Cancer Research medicine.medical_specialty Mycosis fungoides mycosis fungoides business.industry Anti pd 1 medicine.disease Gastroenterology Oncology Atezolizumab Sézary syndrome Internal medicine Relapsed refractory medicine Stage iib business
Zdroj:	European journal of cancer (Oxford, England : 1990). 156
ISSN:	1879-0852
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7063046a0fac73a0bc3d43b2ef299d6 https://pubmed.ncbi.nlm.nih.gov/34649647 Zobrazit plný text záznamu Full Text from ScienceDirect